Do Skinny People Have Visceral Fat?

Do skinny people have visceral fat? Yes, and it is more common than most people realise. Even those with a healthy body weight and normal BMI can carry significant amounts of visceral fat deep within the abdominal cavity, surrounding vital organs such as the liver, pancreas and kidneys. This hidden fat is invisible from the outside and undetectable on scales, yet it carries serious metabolic and cardiovascular risks. Understanding why some slim people accumulate visceral fat, how to assess your own risk, and what steps to take is essential for anyone who wants a complete picture of their health.

Can you be slim but still carry higher-risk fat around your organs?

Yes, slim people can carry significant visceral fat even with a normal BMI, a pattern known as metabolically obese, normal weight (MONW), which BMI alone cannot detect.

Yes, slim people can carry significant amounts of visceral fat around their organs, even when their body weight and body mass index (BMI) appear entirely normal. This phenomenon is sometimes described clinically as "metabolically obese, normal weight" (MONW) or, more recently, as "normal weight obesity". It is more common than many people assume, and it highlights a fundamental limitation of using BMI alone as a measure of health risk.

BMI is calculated from height and weight, so it reflects total body mass but tells you nothing about where fat is stored. A person can weigh within a healthy range while still holding a disproportionate amount of fat in the abdominal cavity, surrounding the liver, pancreas, kidneys and intestines. This internal fat is invisible on the outside and cannot be detected by looking in a mirror or stepping on a set of scales.

Research published in journals including the European Heart Journal has found that a meaningful proportion of people classified as normal weight by BMI have metabolic profiles more typical of those with obesity, including elevated fasting glucose, raised triglycerides and insulin resistance. NICE guidance on obesity and related conditions recognises that waist circumference, used alongside BMI, provides a more complete picture of cardiometabolic risk than BMI alone.^[4][5]

For anyone concerned about their metabolic health, a conversation with a GP is a sensible starting point. A GP can arrange blood tests and, where clinically indicated, refer to specialist services for further assessment. In UK primary care, detailed body composition imaging (such as DEXA or MRI) is not routinely available and is not required for initial risk assessment; BMI, waist circumference, blood pressure and metabolic blood tests are the standard first-line tools. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, for those who want to explore their options alongside NHS care.

What is visceral fat and why does it matter for your health?

Visceral fat surrounds the internal organs and releases hormones, cytokines and free fatty acids that drive insulin resistance, inflammation and increased risk of type 2 diabetes and cardiovascular disease.

Visceral fat is the metabolically active fat stored deep within the abdominal cavity, surrounding the internal organs, as distinct from subcutaneous fat, which sits just beneath the skin. Unlike subcutaneous fat, which is less strongly linked to metabolic risk (and some depots, such as gluteofemoral fat, may even be metabolically protective), visceral fat behaves almost like an endocrine organ: it releases a range of hormones, cytokines and free fatty acids directly into the portal circulation, which drains into the liver.^[7]

This proximity to the liver is one reason visceral fat is considered particularly harmful. Free fatty acids released from visceral deposits travel directly to the liver, where they can promote insulin resistance, raise triglyceride production and contribute to metabolic dysfunction-associated steatotic liver disease (MASLD, previously termed non-alcoholic fatty liver disease or NAFLD). Visceral fat also produces pro-inflammatory cytokines, including interleukin-6 and tumour necrosis factor-alpha, which drive low-grade systemic inflammation.^[8]

The clinical consequences of excess visceral fat include an increased risk of type 2 diabetes, cardiovascular disease, hypertension and certain cancers. NICE guidance on obesity and related conditions recognises that waist circumference, which provides a proxy for central adiposity, is a more useful clinical indicator than BMI alone when assessing cardiometabolic risk.

UK guidance presents two risk bands for waist circumference in white European adults. An "increased risk" threshold applies at 80 cm (31.5 inches) or above in women and 94 cm (37 inches) or above in men. A "high risk" threshold applies at 88 cm (35 inches) or above in women and 102 cm (40 inches) or above in men. Lower thresholds are recommended for people of South Asian, Chinese, Japanese and some other ethnic backgrounds, reflecting differences in fat distribution at equivalent BMI values.^[6] To measure your waist accurately, find the midpoint between your lower rib and the top of your hip bone, wrap a tape measure around this point, breathe out gently, and take the reading without pulling the tape tight.

Visceral fat is not fixed. Evidence from exercise intervention studies suggests it responds to lifestyle changes, particularly regular aerobic exercise and dietary modification, though the relative ease of reduction compared with subcutaneous fat varies between individuals and study designs.

Why do some thin people have high visceral fat levels?

Genetics, physical inactivity, poor diet quality, alcohol, hormonal changes and chronic stress can all cause lean individuals to store fat preferentially in the abdominal cavity rather than subcutaneously.

Several biological, genetic and lifestyle factors explain why some people with a low or normal body weight accumulate visceral fat preferentially. Genetics play a significant role: individuals of South Asian, East Asian and some other ethnic backgrounds tend to store a higher proportion of body fat viscerally at any given BMI compared with people of white European ancestry. This is one reason NICE recommends lower BMI thresholds (23 kg/m² for increased risk and 27.5 kg/m² for high risk, rather than the standard 25 and 30 kg/m²) when assessing obesity-related risk in these populations.

Physical inactivity is another major driver. Skeletal muscle is metabolically active tissue, and people who are sedentary but naturally lean (sometimes called "skinny fat" in lay terms) may have low muscle mass alongside relatively high fat mass, with much of that fat stored viscerally. This body composition pattern can develop in people who do not exercise regularly, even if they eat modestly and never gain visible weight.

Diet quality is associated with visceral fat accumulation. Diets high in refined carbohydrates, added sugars and ultra-processed foods have been linked to greater visceral adiposity in observational and some interventional studies, though the mechanisms are complex and not fully independent of overall energy intake. Alcohol consumption is also associated with preferential visceral fat deposition.

Hormonal factors, including low testosterone in men and changes in oestrogen levels around the menopause in women, shift fat distribution towards the abdomen. Chronic psychological stress raises cortisol, which is associated with visceral fat storage. Poor sleep quality and short sleep duration have also been linked to increased visceral adiposity in research studies, including analyses from UK Biobank cohorts, though causality is not always established.^[9]

What health risks does hidden visceral fat carry?

Hidden visceral fat raises the risk of cardiovascular disease, type 2 diabetes, MASLD and certain cancers, even in people whose body weight appears entirely normal.

Hidden visceral fat carries a range of serious health risks. Cardiovascular disease is among the most significant: visceral fat drives dyslipidaemia (raised triglycerides and low HDL cholesterol), hypertension and arterial inflammation, all of which increase the risk of heart attack and stroke. Cohort studies, including analyses published in the European Heart Journal, have found that people with normal BMI but high central adiposity can have substantially elevated cardiovascular risk, though the magnitude of risk relative to those with clinical obesity varies across studies and populations.

Type 2 diabetes risk is substantially elevated. Visceral fat promotes hepatic and peripheral insulin resistance, impairing the body's ability to regulate blood glucose. People with the MONW phenotype may develop impaired fasting glucose or impaired glucose tolerance without any outward sign of metabolic difficulty, meaning the condition can go undetected until complications arise.

MASLD (previously NAFLD) is closely linked to visceral fat accumulation, even in lean individuals. Left unmanaged, it can progress through stages of inflammation and fibrosis. Certain cancers, including colorectal, pancreatic and postmenopausal breast cancer, have also been associated with excess adiposity in evidence summaries from the World Cancer Research Fund and the International Agency for Research on Cancer, though associations specifically with visceral fat in lean individuals are less well characterised.^[10]

For people who are concerned, a GP can arrange relevant investigations, including fasting lipids, fasting glucose or HbA1c (with thresholds and follow-up pathways set out in NICE guidance NG28 on type 2 diabetes), liver function tests and blood pressure measurement. Waist circumference measurement is a simple, free and clinically informative first step. Management focuses on increasing physical activity in line with UK Chief Medical Officers' guidelines (at least 150 minutes of moderate-intensity aerobic activity per week, plus muscle-strengthening activity), improving diet quality, reducing alcohol intake in line with NHS low-risk guidelines, and addressing sleep and stress.^[12][13] Where clinical thresholds are met, NICE-recommended pharmacological options may be considered as part of a broader weight-management plan, following appropriate clinical assessment and subject to local ICB commissioning and specialist pathway requirements.

Frequently Asked Questions